4SC AG's CSO outlines epigenetics strategy

4SC AG Chief Science Officer Daniel Vitt speaks to Informa senior editor and writer Sten Stovall during the BIO-Europe Spring® partnering conference in Stockholm, Sweden, outlining how the German cancer drug developer will use the EUR 29 million raised in September 2015 in an equity issue for pursuing epigenetic therapies, notably its lead candidate ACE inhibitor resminostat in cutaneous T-cell lymphoma and its 4SC-202 asset in small-cell lung and hematological cancers, and its strategy for regulatory approval.

Interviewer: Sten Stovall – Senior Editor, Pharma Intelligence, In Vivo/Pink Sheet/Scrip
Interviewee: Daniel Vitt – Chief Scientific Officer, 4SC AG